⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8358538 | 1.00 | TSHR (0.43) | — | |
| SCHEMBL2151842 | 1.00 | TSHR (0.43) | — | |
| SCHEMBL1913 | 1.00 | — | — | |
| SCHEMBL4062894 | 0.89 | — | — | |
| Water SCHEMBL11756523 | 0.89 | — | — | |
| SCHEMBL17620634 | 0.89 | — | — | |
| Bromide SCHEMBL10538725 | 0.89 | TSHR (0.38) | — | |
| Ammonia Solution, Strong SCHEMBL1984837 | 0.89 | — | — | |
| SCHEMBL20636746 | 0.89 | — | — | |
| SCHEMBL11632388 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786519-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2023-10-17 | — | — | US | disclosed |
| CN-109535155-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维公司 | 2022-07-12 | — | — | CN | disclosed |
| US-20210346369-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2021-11-11 | — | — | US | disclosed |
| US-20210228565-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-20200345717-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2020-11-05 | — | — | US | disclosed |
| US-20200253954-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2020-08-13 | — | — | US | disclosed |
| EP-2768830-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2018-08-29 | — | — | EP | disclosed |
| US-20180221363-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180140595-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2018-05-24 | — | — | US | disclosed |
| EP-2882439-B1 | APOPTOSIS-INDUCING AGENTS | ABBVIE INC (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-2768830-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2014-08-27 | — | — | EP | disclosed |
| EP-2766361-A1 | 8 - CARBAMOYL - 2 - (2,3- DI SUBSTITUTED PYRID - 6 - YL) -1,2,3,4 -TETRAHYDROISOQUINOLINE DERIVATIVES AS APOPTOSIS - INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2014-08-20 | — | — | EP | disclosed |
| US-20140073640-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. | 2014-03-13 | — | — | US | disclosed |
| WO-2014028381-A1 | APOPTOSIS-INDUCING AGENTS | ABBVIE INC. (US) | 2014-02-20 | — | — | WO | disclosed |
| US-20130096121-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2013055897-A1 | 8 - CARBAMOYL - 2 - (2,3- DI SUBSTITUTED PYRID - 6 - YL) -1,2,3,4 -TETRAHYDROISOQUINOLINE DERIVATIVES AS APOPTOSIS - INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2013-04-18 | — | — | WO | disclosed |
| WO-2013055895-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2013-04-18 | — | — | WO | disclosed |
| US-20130096120-A1 | APOPTOSIS-INDUCED AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-7794915-B2 | Hydrogenated ring-opening metathesis polymer, resist composition comprising the same and patterning method | MITSUI CHEMICALS, INC. (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20080085470-A1 | Hydrogenated ring-opening metathesis polymer, resist composition comprising the same and patterning method | MITSUI CHEMICALS, INC. (JP) | 2008-04-10 | — | — | US | disclosed |